ReviewJournal of hematology & oncology2017
Syk inhibitors in clinical development for hematological malignancies.
Review in Journal of hematology & oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 2 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Pharmacological management of cherubism: A systematic review.Frontiers in endocrinology · 2023Pooled it
- Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2019Pooled it
- Synthesis, molecular modelling and evaluation of (-)-isopulegol-based 2,4-diaminopyrimidines as promising aurora kinase inhibitors.RSC medicinal chemistry · 2026Article
- Non-receptor tyrosine kinase signaling pathways and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Revealing the Pharmacological Mechanism of Tibetan Medicine Wugeng San in Treating Rheumatoid Arthritis Through an Integrated Strategy of Chemical Composition Analysis, Network Pharmacology, Machine Learning, and In Vivo Experiments.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Multi-tyrosine kinase inhibitors: exploring immunomodulatory effects on various immune cell types in cancer.Cancer cell international · 2026Review
- Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets.Molecular systems biology · 2026Article
- Phosphorylation at Y317 on Syk negatively regulates both ITAM- and hemITAM-mediated signaling and function in platelets.Blood advances · 2025Article
- Decipherment of disulfidptosis-related mutation profile, chemosensitivity, and prognosis in diffuse large B-cell lymphoma.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Benchmarking spleen tyrosine kinase (Syk) expression in T- and NK-cell neoplasms: Implications for therapeutic targeting.British journal of haematology · 2025Article
- Integrating QSAR modelling with reinforcement learning for Syk inhibitor discovery.Journal of cheminformatics · 2025Article
- Review
- Primary intestinal T-cell and natural killer-cell lymphomas: Clinicopathologic and prognostic features of 79 cases in South China.American journal of clinical pathology · 2025Article
- Robust collection and processing for label-free single voxel proteomics.Nature communications · 2025Article
- Drug repurposing of fostamatinib against cancer via potential cytotoxicity and immune checkpoint regulation.Frontiers in immunology · 2025Article
- Orchestration of Tumor-Associated Macrophages in the Tumor Cell-Macrophage-CD8International journal of biological sciences · 2025Review
- Resveratrol suppresses OSCC invasion and migration by regulating macrophage polarization via Syk signaling pathway.Frontiers in immunology · 2025Article
- Kidney injury: the spleno-renal connection and splenic tyrosine kinase.Journal of nephrology · 2024Review
- New insights into SYK targeting in solid tumors.Trends in pharmacological sciences · 2024Review
- SYK promotes the formation of neutrophil extracellular traps by inducing PKM2 nuclear translocation and promoting STAT3 phosphorylation to exacerbate hepatic ischemia-reperfusion injury and tumor recurrence.Molecular medicine (Cambridge, Mass.) · 2024Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Several oral Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659 are being assessed in clinical trials. The second generation compound, entospletinib, showed promising results in clinical trials against B-cell malignancies, mainly chronic lymphoid leukemia. Syk inhibitors are being evaluated in combination regimens in multiple malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.